WO2005014787A2

WO2005014787A2 - Genetic elements conferring flower petal-specific transgene expression

Info

Publication number: WO2005014787A2
Application number: PCT/US2004/022343
Authority: WO
Inventors: David Grayson Clark; Harry John Klee; Kenichi Shibuya; Holly Marie Loucas
Original assignee: University Of Florida
Priority date: 2003-07-17
Filing date: 2004-07-13
Publication date: 2005-02-17
Also published as: US7217859B2; US20050044586A1; WO2005014787A3

Abstract

The present invention provides recombinant promoters that drive tissue-specific expression, and transgenes comprising such recombinant promoters. Specifically, the invention provides transgenes comprising a recombinant promoter that drives tissue-specific expression of a heterologous nucleic acid molecule in a floral organ. The invention also provides methods for using such transgenes to produce a protein in a host cell or transgenic plant. The invention further provides methods for producing a transgenic plant that produces, for example, longer-lasting flowers, better fragrance, or better or longer-lasting color as compared to a wild type plant.

Description

GENETIC ELEMENTS CONFERRING FLOWER PETAL-SPECIFIC TRANSGENE EXPRESSION

ACKNOWLEDGEMENT OF FEDERAL RESEARCH SUPPORT This invention was made, at least in part, with funding from the United States Department of Agriculture. Accordingly, the United States Government may have certain rights in this invention.

BACKGROUND OF THE INVENTION

1. Field of the Invention The invention relates to recombinant promoters that are capable of driving tissue-specific expression, and transgenes comprising such recombinant promoters. In particular, the invention relates to transgenes comprising a recombinant promoter capable of driving tissue-specific expression of a heterologous nucleic acid molecule in a floral organ. The invention also relates to methods for using such transgenes to produce a protein in a host cell or transgenic plant. The invention further relates to methods for producing a transgenic plant that produces longer-lasting flowers as compared to a wild type plant.

2. Background of the Invention Ethylene is a plant hormone that plays a critical role in regulating flower senescence in many species. Isolation of several components of the ethylene synthesis and signal transduction pathways has made possible the manipulation of ethylene responses through genetic modification. For example, overexpression of etrl-1, a mutant form of an Arabidopsis ethylene receptor caused decreased sensitivity to ethylene in petunia and carnation and delayed flower senescence. See e.g., Wilkinson et al, (1997) A dominant mutant receptor from Arabidopsis confers ethylene insensitivity in heterologous plants. Nat. Biotechnol. 15: 444-447; Bovy et al, (1999) Heterologous expression of the Arabidopsis etrl-1 allele inhibits the senescence of carnation flowers. Mol. Breed. 5: 301-308). Although manipulation of ethylene responses is useful to prevent flower senescence, there are several potential disadvantages to this approach. The greatest disadvantage is that where constitutive promoters, such as Cauliflower mosaic virus 35S promoters, were used to drive transgene expression, changes occurred in ethylene response even in untargeted tissues. In fact, etrl-1 has been shown to have negative effects when expressed ectopically in vegetative tissues such as roots and stems. For example, ethylene-insensitive petunia that harbors Cauliflower mosaic virus 35S promoter driven etrl-1 displays reduced adventitious rooting. See e.g., Clark et al., (1999) Root formation in ethylene-insensitive plants. Plant Physiol. 121: 53-60. These plants also show a great deal of premature death. See e.g., Shibuya et al., (2004) The central role of PhELN2 in ethylene responses throughout plant development in petunia (Unpublished). Furthermore, overexpression of etrl-1 in tobacco increased susceptibility to fungal pathogens infecting roots. See e.g., Knoester et al., (1998) Ethylene-insensitive tobacco lacks non-host resistance against soil-bome fungi. Proc. Natl. Acad. Sci. 95: 1933-1937. Thus, altering ethylene sensitivity throughout the plant causes negative effects in untargeted tissues. Therefore, there remains a need in the art for recombinant promoters that are capable of driving tissue-specific expression of an isolated nucleic acid molecule operably linked to the promoter. In particular, there is a need in the art for recombinant promoters that are capable of driving expression of isolated nucleic acid molecules in a floral organ, and transgenes comprising such recombinant promoters. The development of such transgenes would have wide application in the production of transgenic plants expressing commercially desirable proteins, such as ethylene receptor etrl-1, in floral organs.

SUMMARY OF THE INVENTION The present invention provides recombinant promoters that drive tissue- specific expression of an isolated nucleic acid molecule operably linked to the promoter. Specifically, the invention provides a recombinant promoter comprising the nucleotide sequence of any of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4; or a portion of the nucleotide sequence of any of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4. In one embodiment, the recombinant promoters of the invention drive expression of the nucleic acid molecule in a floral organ. The present invention also provides vectors, host cells, and transgenic plants comprising recombinant promoters capable of driving tissue-specific expression of an isolated nucleic acid molecule operably linked to the promoter. The present invention further provides transgenes comprising recombinant promoters that drive tissue-specific expression and an isolated nucleic acid molecule operably linked to the promoter. Specifically, the invention provides transgenes in which the recombinant promoter comprises the nucleotide sequence of any of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4; or a portion of the nucleotide sequence of any of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4. In one embodiment, the transgenes of the invention comprise recombinant promoters that drive expression of the nucleic acid molecule in a floral organ. The present invention also provides vectors, host cells, and transgenic plants comprising transgenes containing recombinant promoters that drive tissue-specific expression of an isolated nucleic acid molecule operably linked to the promoter. The present invention further provides methods for using transgenes comprising recombinant promoters that drive tissue-specific expression of an isolated nucleic acid molecule operably linked to the promoter to produce a protein in a host cell or transgenic plant. In one method of the invention, a protein encoded by a transgene comprising a recombinant promoter capable of driving tissue-specific expression of an isolated nucleic acid molecule operably linked to the promoter is produced by introducing the transgene into a host cell and then culturing the host cell under suitable conditions to express the protein. In another method of the invention, a protein encoded by a transgene comprising a recombinant promoter that drives tissue- specific expression of an isolated nucleic acid molecule operably linked to the promoter is produced by introducing the transgene into a plant cell or tissue and then regenerating a transgenic plant from the transformed plant cell or transformed plant tissue. The invention also provides methods for producing a transgenic plant that produces longer-lasting flowers as compared to a wild type plant. In one method of the invention, a transgene comprising a recombinant promoter that drives tissue- specific expression of an isolated nucleic acid molecule operably linked to the promoter and a heterologous sequence for ethylene receptor etrl-1 is introduced into a plant cell or plant tissue and then regenerating a transgenic plant from the transformed plant cell or transformed plant tissue. Specific embodiments of the present invention will become evident from the following more detailed description of certain preferred embodiments and the claims. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 shows the results of RNA gel blot analysis using probes derived from flower-specific genes identified by cDNA microarray analysis; gene expression was analyzed in RNA isolated from petals at anthesis (first lane), leaves (second lane), stems (third lane), and roots (fourth lane). Twenty μg of total RNA isolated from petals (at anthesis), leaves, stems and roots was separated on a formaldehyde-agarose gel and blotted onto a nylon membrane. The blots were hybridized with 32p-labeled cDNA probes and exposed to autoradiography film for 48hr at -80C. P, petal; L, leaf; S, stem; R, root. Figure 2 shows the results of RNA gel blot analysis of flower-specific genes identified in the first screen shown in Figure 1. Total RNA was isolated from petal at three developmental stages (bud, pre-anthesis and anthesis), style, ovary, receptacle anther, leaf, stem root, and crown). Thirty μg of total RNA was separated on a gel and blotted onto a nylon membrane. The blots were hybridized with 32P-labeled cDNA probes and exposed to films for 7 days at -80C. Figure 3 shows the results of RNA gel blot analysis of flower-specific genes identified in the second screen shown in Figure 2. Poly(A) RNA was isolated from bud, flower at anthesis, leaf, stem, root and crown. Two μg of poly(A) RNA was separated on a gel and blotted onto a nylon membrane. The blots were hybridized with 32P-labeled cDNA probes and exposed to films for 7 days at -80C. Figure 4 shows a schematic of two types of transgene constructs that were prepared using flower-specific (FS) promoters and either a β-glucuronidase reporter gene (GUS) or a mutated Arabidopsis ethylene receptor etrl-1 sequence (etrl-1). Figure 5 shows the expression of GUS in the flowers (A), leaves (B), and roots (C) of plants transformed with a transgene construct containing the FS19, FS26 and FS37 promoters.

DETAILED DESCRIPTION OF THE INVENTION The present invention provides recombinant promoters that drive tissue- specific expression, and transgenes comprising such recombinant promoters. In particular, the invention provides transgenes comprising a recombinant promoter that drives tissue-specific expression of a nucleic acid molecule in a floral organ. The invention also provides methods for using such transgenes to produce a protein in a host cell or transgenic plant. The invention further provides methods for producing a transgenic plant that produces longer-lasting flowers as compared to a wild type plant. The term "recombinant promoter" or "promoter," as used herein, means a nucleic acid molecule usually found upstream, i.e., 5', of a coding sequence that directs transcription of a nucleic acid sequence into mRNA. A promoter typically comprises a recognition site capable of directing RNA polymerase to initiate RNA synthesis at an appropriate transcription initiation site. A promoter can additionally comprise other sequences such as upstream promoter elements that can influence transcription initiation rate. The activity or strength of a promoter can be measured by the amount of mRNA it produces or by the amount of protein accumulation in a cell or tissue relative to a promoter whose transcriptional activity is known. The activity or strength of a promoter can be expressed relative to a well-characterized promoter. For example, a promoter can be operably linked to a reporter sequence (e.g., GUS) and introduced into a specific cell type. A known promoter can be similarly prepared and introduced into the same cell. Transcriptional activity of the promoter is then determined by comparing the amount of reported expression, relative to the known promoter. An isolated promoter sequence of the instant invention can be modified to provide for a range of expression levels of the coding sequence. Less than the entire promoter region can be used and the ability to drive tissue-preferred expression retained. Expression levels of mRNA can be decreased with deletions of portions of the promoter sequence. Thus, the promoter can be modified to be a weak or strong promoter. A weak promoter drives expression of a coding sequence at a low level. A strong promoter drives expression of a coding sequence at a high level. Enhancers can be used in combination with the promoters of the invention. Enhancers are nucleotide sequences that increase expression. Enhancers are known in the art and include, for example, an SV40 enhancer region and a 35S enhancer element. In one embodiment, recombinant promoters of the invention comprise the nucleotide sequence of any of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4. Recombinant promoters of the invention also include portions of the nucleotide sequence of any of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4 that drive tissue-specific expression of an isolated nucleic acid molecule. One embodiment of the invention provides a minimal promoter. A minimal promoter will typically comprise a TATA box and transcriptional start sequence, but will not contain additional stimulatory and repressive elements. The boundaries defining the minimal promoter sequence can be ambiguous. That is, the nucleotide positions defining the 5' and 3' ends of a minimal promoter can vary slightly depending on, for example, the expression-reporter system used. The boundaries defining the minimal promoter can be determined using known techniques, described in, for example, Fang et al, (1989) Plant Cell 1:141-50 and Odell et al, (1985) Nature 313:810-2. The invention also provides promoters wherein promoter sequences are duplicated. The duplication can provide enhanced promoter activity. For example, two or more copies of an enhancer element in tandem often results in increased expression levels. See e.g., U.S. Pat. No. 5,424,200; Maiti et al, (1997) Transgenic Res. 6:143-56; and Maiti & Shepard (1998) Biochem. Biophys. Res. Commun. 244:440-44. The invention also provides chimeric promoters comprising a portion of a promoter of the invention. For example, a chimeric promoter can comprise one or more promoter elements of the invention combined with one or more promoter elements derived from another promoter of the invention or any other promoter. The portion of a chimeric promoter that is not derived from a promoter of the invention can be derived from, for example, another plant promoter or a viral promoter, or from any other naturally occurring promoter. Alternatively, that portion can be synthetic or a modified variation or a naturally-occurring promoter.

Fragments or portions of a promoter nucleotide sequence disclosed herein are also encompassed by this invention. Such fragments will comprise at least about 20, 50, 75, 100, 150, 200, 300, 400, 500, 750, 1,000, 1,250, 1,500, 1,750, or 2,000 contiguous nucleotides of the promoter nucleotide sequence disclosed herein. Such fragments will usually comprise the TATA recognition motif of the promoter sequence. A fragment or portion of the invention can comprise one or more TATA signals and/or one or more Transcription Factor Binding sites as shown in Tables 2 and 3 below. Such fragments can be obtained by use of restriction enzymes to cleave the naturally-occurring promoter nucleotide sequences disclosed herein; by synthesizing a nucleotide sequence; through the use of, e.g., PCR technology. See e.g., Mullis et al. (1987) Methods Enzymol. 155:335-350, and Erlich, ed. (1989) PCR Technology (Stockton Press, New York). Fragments of promoter sequences are capable of driving tissue-preferred expression and are useful as probes to identify similar sequences. An example of a promoter fragment or a portion thereof is a promoter formed by one or more deletions from a larger promoter. The 5' portion of a promoter up to the TATA signal near the transcription start site can typically be deleted without abolishing promoter activity, as described by Zhu et al, The Plant Cell 7: 1681-89 (1995). Such fragments retain promoter activity, particularly the ability to drive expression in specific tissues. Promoter activity can be measured by, for example, RNA gel blot analysis and reporter activity measurements when using transcriptional fusions. See, for example, Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual (2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.). The term "isolated nucleic acid molecule" is used to refer to a nucleic acid molecule that (1) has been separated from at least about 50 percent of proteins, lipids, carbohydrates, or other materials with which it is naturally found when total nucleic acid is isolated from source cells, (2) is not linked to all or a portion of a polynucleotide to which the "isolated nucleic acid molecule" is linked in nature, (3) is operably linked to a polynucleotide which it is not linked to in nature, or (4) does not occur in nature as part of a larger polynucleotide sequence. Preferably, the isolated nucleic acid molecule of the present invention is substantially free from any other contaminating nucleic acid molecules or other contaminants that are found in its natural environment that would interfere with, for example, its use in polypeptide production. The term "nucleic acid sequence" or "nucleic acid molecule" is used to refer to a DNA or RNA sequence. The term encompasses molecules formed from any of the known base analogs of DNA and RNA such as, but not limited to 4- acetylcytosine, 8-hydroxy-N6-methyladenosine, aziridinyl-cytosine, pseudoisocytosine, 5-(carboxyhydroxylmethyl) uracil, 5-fiuorouracil, 5-bromouracil, 5-carboxymethylaminomethyl-2-thiouracil, 5-carboxy-methylaminomethyluracil, dihydrouracil, inosine, N6-iso-pentenyladenine, 1-methyladenine, 1- methylpseudouracil, 1-methylguanine, 1-methylinosine, 2,2-dimethyl-guanine, 2- methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6- methyladenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyamino- methyl-2-thiouracil, beta-D-mannosylqueosine, 5' -methoxycarbonyl-methyluracil, 5- methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid, oxybutoxosine, pseudouracil, queosine, 2- thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, N- uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid, pseudouracil, queosine, 2-thiocytosine, and 2,6-diaminopurine. The term "identity," as known in the art, is used to refer to a relationship between two or more nucleic acid molecules or polypeptide molecules, as determined by comparing the sequences. In the art, "identity" also means the degree of sequence relatedness between nucleic acid molecules or polypeptide molecules, as the ease may be, as determined by the match between strings of two or more nucleotide or two or more amino acid sequences. "Identity" measures the percent of identical matches between the smaller of two or more sequences with gap alignments (if any) addressed by a particular mathematical model or computer program (i.e., "algorithms"). The term "tissue-specific expression/' as it relates to promoter activity, refers to the ability of a promoter to drive the expression of an isolated nucleic acid molecule in less than all of the tissues of an organism into which the promoter and nucleic acid molecule are introduced. The tenn "constitutive expression," as it relates to promoter activity, refers to the ability of a promoter to drive the expression of an isolated nucleic acid molecule in substantially all of the tissues of an organism into which the promoter and nucleic acid molecule are introduced. In one embodiment, the recombinant promoters of the invention drive tissue-specific expression of an isolated nucleic acid molecule. In another embodiment, the recombinant promoters of the invention drive expression of an isolated nucleic acid molecule in a specific tissue. In yet another embodiment, recombinant promoters of the invention drive the expression of an isolated nucleic acid molecule in a floral organ. Promoters of the invention are floral organ specific. That is, the promoters drive expression of a nucleic acid sequence such that the level of the resulting mRNA in the floral organ is expressed at a level that is about 5 fold, 10 fold, 100 fold, 1,000 fold, or more higher than another tissue or organ. The level of mRNA can be measured either at a single time point or at multiple time points and as such the increase in mRNA can be an average increase or an extrapolated value derived from experimentally measured values. The recombinant promoters and nucleic acid molecules of the invention can readily be obtained in a variety of ways including, without limitation, chemical synthesis, genomic library screening, expression library screening, or PCR amplification of genomic DNA. Recombinant nucleic acid methods used herein are generally those set forth in Sambrook et al, Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory Press, 1989) or Current Protocols in Molecular Biology (Ausubel et al, eds., Green Publishers Inc. and Wiley and Sons 1994). One method for obtaining the recombinant promoters and nucleic acid molecules of the invention is the polymerase chain reaction (PCR). In this method, genomic DNA isolated from plant tissue is used as a template for PCR amplification. Two primers, typically complementary to two separate regions of a particular nucleic acid sequence, are then added to the nucleic acid sequence along with a polymerase such as Taq polymerase, and the polymerase amplifies the region of the nucleic acid sequence between the two primers. Another method for obtaining the recombinant promoters and nucleic acid molecules of the invention is chemical synthesis using methods well known to the skilled artisan such as those described by Engels et al, 1989, Angew. Chem. Intl. Ed. 28:716-34. These methods include, mter alia, the phosphotriester, phosphoramidite, and H-phosphonate methods for nucleic acid synthesis. A preferred method for such chemical synthesis is polymer-supported synthesis using standard phosphoramidite chemistry. Typically, the desired nucleic acid molecule will be several hundred nucleotides in length. Nucleic acids larger than about 100 nucleotides can be synthesized as several fragments using these methods. The fragments can then be ligated together to form the full-length nucleotide sequence. Other methods known to the skilled artisan can be used as well. The term "transgene," as used herein, refers to a chimeric gene comprising a recombinant promoter and an isolated nucleic acid molecule operably linked to the promoter, wherein the chimeric gene is capable of integrating into the germ line of an organism and being expressed. In one embodiment, the transgenes of the invention comprise a recombinant promoter operably linked to a nucleic acid molecule encoding ethylene receptor etrl-1. In other embodiments, transgenes of the invention comprise a recombinant promoter operably linked to a nucleic acid molecule encoding, for example polypeptides that play a role in determining flower pigmentation, fragrance, seed yield. Other nucleic acid molecules can encode, for example, proteins having commercial value such as pharmaceuticals. The term "operably linked" is used to refer to an arrangement of flanking sequences wherein the flanking sequences so described are configured or assembled so as to perform their usual function. Thus, a flanking sequence operably linked to a coding sequence can be capable of effecting the replication, transcription, or translation of the coding sequence. For example, a coding sequence is operably linked to a promoter when the promoter directs transcription of that coding sequence. A flanking sequence need not be contiguous with the coding sequence, so long as it functions correctly. Thus, for example, intervening untranslated yet transcribed sequences can be present between a promoter sequence and the coding sequence and the promoter sequence can still be considered "operably linked" to the coding sequence. The term "vector" is used to refer to any molecule (e.g., nucleic acid, plasmid, or virus) used to transfer coding information to a host cell. Vectors containing the transgenes of the invention can be prepared by inserting a recombinant promoter and an isolated nucleic acid molecule into an appropriate vector using standard ligation techniques. Typically, the vectors of the invention will also contain sequences (in addition to the recombinant promoter and isolated nucleic acid molecule) for plasmid maintenance and for cloning and expression of exogenous nucleotide sequences. Such sequences, or "flanking sequences," typically include one or more of the following: one or more enhancer sequences, an origin of replication, a transcriptional termination sequence, a sequence encoding a leader sequence for polypeptide secretion, a polyadenylation sequence, a polylmker region for inserting the nucleic acid encoding the polypeptide to be expressed, and a selectable marker element. In preferred embodiments, a recombinant promoter and isolated nucleic acid molecule are introduced into a transformation vector such as, pHK, for example, that contains spectromycin resistance gene as a selectable marker for host bacteria and a kanamycin resistance gene as a selectable marker for a host plant. Flanking sequences can be homologous (i.e., from the same species or strain as the host cell), heterologous (i.e., from a species other than the host cell species or strain), hybrid (i.e., a combination of flanking sequences from more than one source), or synthetic. As such, the source of a flanking sequence may be any prokaryotic or eukaryotic organism, any vertebrate or invertebrate organism, or any plant, provided that the flanking sequence is functional in, and can be activated by, the host cell machinery. An origin of replication is typically a part of those prokaryotic expression vectors purchased commercially, and the origin aids in the amplification of the vector in a host cell. If the vector of choice does not contain an origin of replication site, one may be chemically synthesized based on a known sequence, and ligated into the vector. A transcription termination sequence is typically located 3 ' of the end of a polypeptide coding region and serves to terminate transcription. While a transcription termination sequence is easily cloned from a library or even purchased commercially as part of a vector, it can also be readily synthesized using methods for nucleic acid synthesis such as those described herein. In one embodiment, vectors of the invention contain a nopaline synthase gene terminator sequence (NOS3') for terminating transcription of an isolated nucleic acid molecule operably linked to the recombinant promoter. A selectable marker gene element encodes a protein necessary for the survival and growth of a host cell grown in a selective culture medium. Typical selection marker genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g., ampicillin, tetracycline, or kanamycin; (b) complement auxotrophic deficiencies of the cell; or (c) supply critical nutrients not available from complex media. Selectable markers include, for example, kanamycin resistance, the ampicillin resistance, and tetracycline resistance. Neomycin resistance can also be used for selection in prokaryotic and eukaryotic host cells. Vectors of the invention can be constructed from a starting vector such as a commercially available vector. Such vectors may or may not contain all of the desired flanking sequences. Where one or more of the flanking sequences described herein are not already present in the vector, they can be individually obtained and ligated into the vector. Methods used for obtaining each of the flanking sequences are well known to one skilled in the art. The term "host cell," as used herein, refers to a cell that has been transformed, or that can be transformed with a nucleic acid sequence. The term includes the progeny of the parent cell, whether or not the progeny is identical in morphology or in genetic make-up to the original parent, so long as the selected nucleic acid is present. The vectors of the invention can be inserted into a suitable host cell for amplification or polypeptide expression. The transformation of vectors of the invention into a selected host cell can be accomplished by well known methods including transfection, infection, calcium chloride, electroporation, microinjection, lipofection, DEAE-dextran method, or other known techniques. The method selected will in part be a function of the type of host cell to be used. These methods and other suitable methods are well known to the skilled artisan, and are set forth, for example, in Sambrook et al, supra. The term "transfection," as used herein, refers to uptake of foreign or exogenous nucleic acid by a cell, and a cell has been "transfected" when the exogenous nucleic acid has been introduced inside the cell membrane. A number of transfection techniques are well known in the art. Such techniques can be used to introduce one or more exogenous nucleic acid moieties into suitable host cells. The term "transformation" is used to refer to a change in a cell's genetic characteristics, and a cell has been transformed when it has been modified to contain a new nucleic acid. For example, a cell is transformed where it is genetically modified from its native state. Following transfection, for example, transforming nucleic acid can recombine with that of the cell by physically integrating into a chromosome of the cell, can be maintained transiently as an episomal element without being replicated, or can replicate independently as a plasmid. A cell is considered to have been stably transformed when the nucleic acid is replicated with the division of the cell. The term "naturally occurring" or "native" when used in connection with biological materials such as nucleic acid molecules, polypeptides, host cells, and the like, refers to materials that are found in nature and are not manipulated by man. Similarly, "non-naturally occurring" or "non-native" as used herein refers to a material that is not found in nature or that has been structurally modified or synthesized by man. Host cells may be prokaryotic host cells (such as E. coli), eukaryotic host cells (such as a yeast, insect, or vertebrate cell), or plant cells. In a preferred embodiment, the host cell is a plant cell. A number of suitable host cells are known in the art and many are available from the American Type Culture Collection (ATCC), Manassas, VA. Examples include, but are not limited to, plants whose flower senescence is accelerated by ethylene, for example, Petunia (Petunia hybrida), Carnation (Dianthus caryophyllus), Cyclamen (Cyclamen spp.), Delphinium (Delphinium spp.), Geranium (Pelargonium & Geranium spp.), Sweet pea (Lathyrus odoratus), Snapdragon (Antirrhinum ma us), Begonia (Begonia sp.), Rose (Rosa spp.). Candidate cells can be genotypically deficient in the selectable marker gene, or can contain a dominantly acting selectable marker gene. Similarly useful as host cells suitable for the present invention are bacterial cells. For example, the various strains of E. coli (e.g., HB101, DH5α, DH10, and MCI 061) are well-known as host cells in the field of biotechnology. Various strains of B. subtilis, Pseudomonas spp. , other Bacillus spp. , Streptomyces spp. , and the like can also be employed in this method. Host cells comprising transgenes or vectors of the invention can be cultured using standard media well known to the skilled artisan. The media will usually contain all nutrients necessary for the growth and survival of the cells. Typically, an antibiotic or other compound useful for selective growth of transfected or transformed cells is added as a supplement to the media. The compound to be used will be dictated by the selectable marker element present on the vector with which the host cell was transformed. For example, where the selectable marker element is kanamycin resistance, the compound added to the culture medium will be kanamycin. Other compounds for selective growth include ampicillin, tetracycline, and neomycin. The amount of protein produced by a host cell can be evaluated using standard methods known in the art. Such methods include, without limitation, Western blot analysis, SDS-polyacrylamide gel electrophoresis, non-denaturing gel electrophoresis, High Performance Liquid Chromatography (HPLC) separation, immunoprecipitation, or activity assays such as DNA binding gel shift assays. In a preferred embodiment, a commercially desirable protein is produced in a transgenic plant by introducing a transgene comprising a recombinant promoter and an isolated nucleic acid molecule encoding the commercially desirable protein, wherein the nucleic acid molecule is operably linked to the promoter, into a plant cell or tissue; regenerating a transgenic plant from the transformed plant cell or transformed plant tissue; and then growing the transgenic plant under suitable conditions to express the protein. In one embodiment, a vector comprising the transgene is introduced into a plant cell or tissue using Agrobacterium-mediated transformation. The transformation vectors are transferred to Agrobαcterium through triparental mating. Plant tissue is transformed with this construct through -4grob cteπ^'u»z-mediated transformation. Transfonnants are selected on tissue culture media containing appropriate antibiotics. In another embodiment, the transgene encodes ethylene receptor etrl-1, and the transgenic plants thus obtained produce longer-lasting flowers as compared to a wild type plant The invention also provides methods for producing transgenic plants or plant cells comprising a promoter of the invention operably linked to a heterologous nucleic acid sequence. Other nucleic acid sequences can also be introduced into the plant or plant cell along with the promoter. These other nucleic acid sequences can include 3' transcriptional tenninators, 3' polyadenylation signals, other untranslated nucleic acid sequences, transit or targeting sequences, selectable markers, enhancers, and operators. A suitable plant cell is selected and transformed with a recombinant vector. The transformed host cell is cultured under conditions effective to produce a plant. The regeneration, development, and cultivation of plants from transformed plant protoplast or explants is well know in the art. See e.g., Dodds & Roberts, Experiments in Plant Tissue Culture, 1995, Cambridge University Press, New York; Davey (ed.), Agrobacterium Protocols, 1995, Humana Press, New Jersey; Smith, Plant Tissue Culture, 2000, Academic Press, New York. For example, transformants are generally cultured in the presence of a selective media that selects for successfully transformed cells and induces the regeneration of plant shoots. The shoots are transferred to an appropriate root-inducing medium containing a selective agent and an antibiotic to prevent bacterial growth. Shoots that develop roots are transplanted to soil or other media to allow the continued development of roots. The Examples, which follow, are illustrative of specific embodiments of the invention, and various uses thereof. They are set forth for explanatory purposes only, and are not to be taken as limiting the invention.

EXAMPLE 1 Identification of Flower Petal-Specific Genes Flower petal-specific genes were identified by first preparing individual cDNA libraries from petunia flowers (Petunia hybrida cv. Mitchell) isolated either (1) at various stages of floral development, (2) following pollination, or (3) following exogenous ethylene treatment. The first cDNA library (floral development) was prepared from pooled mRNA isolated from whole flowers collected at six developmental stages between floral initiation and anthesis. The second cDNA library (post-pollination) was prepared from pooled mRNA isolated from whole flowers that were pollinated at anthesis and then collected at regular intervals for 48 hours following pollination. The final cDNA library (ethylene-treated) was constructed from pooled mRNA isolated from whole flowers that were treated with 2 μL/L ethylene at anthesis and then collected at regular intervals until 24 hours following the onset of treatment. Each cDNA library was prepared using bacteriophage vectors that allowed for uni-directional cloning of the cDNA inserts (λ ZAP^® II; Stratagene; La Jolla, CA). Several random cDNA clones from each library were sequenced to assess the quality of the libraries, and then primary (unamplified) library stocks were excised and introduced into bacterial cells. E. coli containing the excised phagemids were plated, and 10% of the colonies on each plate were selected at random for DNA sequencing analysis. DNA sequence data obtained from approximately 6805 clones indicated that between 40-50% of these clones contained redundant sequences, resulting in the identification of approximately 3200 non-redundant cDNAs. To prepare microarrays containing the non-redundant sequences, bacterial cultures containing each of the non-redundant cDNAs were grown up, and the cDNA sequences were isolated by PCR amplification. Microarrays were generated using an Affymetrix 418™ arrayer (Santa Clara, CA) by spotting the PCR-amplified cDNAs in duplicate onto glass microscope slides coated with poly-L-lysine solution. The slides were then UV crosslinked and denatured prior to DNA hybridization analysis. Flower-specific genes were identified on the microarrays by hybridization with probes generated from (a) total RNA extracted from P. hybrida cv Mitchell's petals and (b) pooled total RNA extracted from vegetative tissues (i.e., leaf, stem, and root). Fluorescent probes were prepared by reverse transcribing mRNA from total RNA using dye-specific primers (cy3 or cy5; Submicro EX Expression Array Detection Kit; Genisphere; Hatfield, PA), and then were hybridized to the microarray slides for 24 hours. Following hybridization, the slides were washed to remove unbound probe, and then scanned immediately using an Affymetrix scanning microscope. Scaimed images were analyzed for intensity readings using Affymetrix Jaguar 1.0 software. The intensity ratios for the cy3 and cy5 dyes at each spot were used to identify flower-specific genes. Each hybridization experiment was conducted in triplicate by analyzing duplicate spots on tliree individual slides. Only genes that yielded a flower-specific signal at four or more of the six spots tested were considered for further analysis. Based on microarray analysis, 47 genes were identified as being flower-specific. RNA gel blot analysis was performed to confirm the flower-specific expression of genes identified by microarray analysis. RNA gel blots were prepared by first separating 20 μg of total RNA from petal, leaf, stem, and root tissue on a formaldehyde-agarose gel, and then blotting the gels onto a nylon membrane. Blots were hybridized with ³²P-labeled cDNA probes generated from the flower-specific genes to be tested, and then the blots were washed and exposed to film for 48 hours (Figure 1). Based on the results of a first screen of the flower-specific genes identified by microarray analysis, sixteen genes were confirmed as being flower- specific, and their full-length cDNA inserts were re-sequenced. Sequence alignment analysis revealed that ten of the sixteen genes were unique. Subsequently, second and third screens were performed using either 30 μg of total RNA (second screen; Figure 2) or 2 μg of Poly-(A) RNA (third screen; Figure 3) extracted from several tissues and developmental stages. Four flower-specific genes, designated as FS19, FS26, FS37, and FS44, were selected for promoter isolation. See Table 1. BLAST analysis revealed that flower- specific genes FS37 and FS44 encode proteins that are identical to the floral binding proteins FBP1 and FBP3, respectively (Angenent et al, 1992, Plant Cell 4:983-93; Angenent et al, 1994, Plant J. 5:33-44). The flower-specific gene FS19 was found to encode a protein sharing 56% identity with a putative amp-binding protein in Arabidopsis thaliana that contains a conserved amp-binding domain. The flower- specific gene FS26 was found to encode a protein sharing 33% identity with an unknown protein in Arabidopsis thaliana, and a search of the conserved domain database showed that this protein contained a RING-finger (Really Interesting New Gene) domain.

EXAMPLE 2 Identification of Promoter Elements Conferring Flower Petal-Specific Gene Expression A petunia genomic library was constructed in order to isolate the promoters of the flower-specific genes identified in Example 1. Genomic DNA was isolated from the flower buds of P. hybrida cv. Mitchell, partially digested with Sau3AI, and then ligated into the ZAP express vector (Stratagene). The primary genomic library (1 x 10⁶ pfu) was plated on NZY agar plates, and plaques were transferred onto nitrocellulose membranes. The membranes were then hybridized with P-labeled cDNA for FS19, FS26, FS37, and FS44, washed, and exposed to film. Following a secondary screen, insert-containing phagemids were obtained from the isolates by in vivo excision. A 4.4 kb genomic DNA fragment for the flower-specific gene FS37 was isolated and sequenced. For the other three genes (FS19, FS26, and FS44), only short genomic fragments were isolated. In order to obtain longer sequences of the promoter regions for these tliree genes, genome walking was performed with the Universal GenomeWalker Kit (BD Biosciences; Palo Alto, CA) according to the manufacture's protocols. Upstream DNA sequences of 3.6 kb, 1.8 kb and 2J kb, starting from the ATG translation initiation site for FS19, FS26, and FS44, respectively, were obtained by multiple genome walking. A 1074 bp region upstream of the FS44 translation start site was found to be identical to a sequence previously reported as the FBP1 promoter (Angenent et al, 1992).

EXAMPLE 3 Preparation of Constructs Containing Flower Petal-Specific Promoter Elements The upstream regions of the flower-specific genes, which contain the ATG translation initiation sites, were amplified by PCR using genomic DNA as a template. PCR products of 2932 bp, 1545 bp, 3040 bp, and 2269 bp corresponding to the promoters for the flower-specific genes FS19, FS26, FS37, and FS44, respectively, were fused to either a GUS (β-glucuronidase) reporter gene (Jefferson et al, 1987, EMBO J. 20:3901-07) or a mutated Arabidopsis ethylene receptor etrl-1 sequence (Chang et al, 1993, Science 262:539-44), and then were followed by a NOS3' sequence (nopaline synthase gene terminator sequence). It has been reported that the etrl-1 gene confers ethylene insensitivity in heterologous plants including petunia, and results in the extension of flower-life (Wilkinson et al, 1997, Nat. Biotechnol. 15:444-47). To generate transgene constructs (Figure 4), the resulting chimeric genes were inserted into the plant transformation vector pHK, which contains the selectable marker gene NPT II (neomycin phosphotransferase II). Leaf explants from P. hybrida cv. Mitchell sterile stock plants were transformed with the transgene constructs as described in Jorgensen et al, 1996, Plant Mol. Biol. 31:957-73. Transformants were selected on MS media containing 150 μg/mL kanamycin and rooted on MS media containing 200 μg/mL kanamycin. Thirty rooted plants were transferred in soil and grown in normal green house conditions. GUS expression analysis was performed as described in Jefferson et al, 1987, Plant Mol. Biol. Reporter 5:387-405. Figures 5A-5B show the expression of GUS in the flowers and leaves of plants transformed with a transgene construct containing the FS37 promoter.

EXAMPLE 4 Identification of TATA signals and Transcription Factor Binding Sites The promoters were analyzed for putative TATA signals using the WWW Signal Scan (Prestridge, D.S. (1991) SIGNAL SCAN: A computer program that scans DNA sequences for eukaryotic transcriptional elements. CABIOS 7: 203-206) and the PLACE Web Signal Scan (Higo et al. (1999) Plant cis-acting regulatory DNA elements (PLACE) database. Nucleic Acids Research 27: 297-300; Prestridge, (1991) SIGNAL SCAN: A computer program that scans DNA sequences for eukaryotic transcriptional elements. CABIOS 7: 203-206). The results are shown in Table 2.

Table 2.

The promoters were analyzed for putative transcription factor binding sites using TFSEARCH (See Heinemeyer et al. (1998) Databases on Transcriptional Regulation: RANSFAC, TRRD, and COMPEL. Nucleic Acids Res. 26, 364-370). The results are shown in Table 3.

Table 3.

It should be understood that the foregoing disclosure emphasizes certain specific embodiments of the invention and that all modifications or alternatives equivalent thereto are within the spirit and scope of the invention as set forth in the appended claims. All patents, patent applications, and other scientific or technical writings referred to anywhere herein are incorporated by reference in their entirety. The invention illustratively described herein suitably can be practiced in the absence of any element or elements, limitation or limitations that are not specifically disclosed herein. Thus, for example, in each instance herein any of the terms "comprising", "consisting essentially of, and "consisting of may be replaced with either of the other two terms. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by embodiments, optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the description and the appended claims. In addition, where features or aspects of the invention are described in terms of Markush groups or other grouping of alternatives, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group or other group.

Claims

WHAT IS CLAIMED IS:

1. A recombinant promoter comprising: (a) a nucleotide sequence of any of SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4; or (b) a portion of a nucleotide sequence of any of SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4; wherein the promoter drives tissue-specific expression of an isolated nucleic acid molecule operably linked to the promoter.

2. The recombinant promoter of claim 1 , wherein the promoter drives expression of the nucleic acid molecule in a floral organ.

3. A vector comprising the recombinant promoter of claim 1.

4. A transgenic plant comprising the vector of claim 3.

5. A host cell comprising the vector of claim 3.

6. The host cell of claim 5, wherein the host cell is a plant cell.

7. A transgenic plant comprising the host cell of claim 5.

8. A transgene comprising the promoter of claim 1 and an isolated nucleic acid molecule operably linked to the promoter.

9. The transgene of claim 8, wherein the promoter drives expression of the nucleic acid molecule in a floral organ.

10. The transgene of claim 8, wherein the nucleic acid molecule encodes ethylene receptor etrl-1.

11. A vector comprising the transgene of claim 8.

12. The vector of claim 11 , wherein the nucleic acid molecule encodes ethylene receptor etrl-1.

13. A transgenic plant comprising the vector of claim 11.

14. A host cell comprising the vector of claim 11.

15. The host cell of claim 14, wherein the host cell is a plant cell.

16. A transgenic plant comprising the host cell of claim 14.

17. A method for producing a protein encoded by the transgene of claim 8 in a host cell comprising: (a) introducing the transgene of claim 8 into the host cell; and (b) culturing the host cell under suitable conditions to express the protein.

18. The method of claim 17, wherein the host cell is a plant cell.

19. The method of claim 18, wherein the transgene encodes ethylene receptor etri -1.

20. A method for producing a protein encoded by the transgene of claim 8 in a transgenic plant comprising: (a) introducing the transgene of claim 8 into a plant cell or plant tissue; (b) regenerating a transgenic plant from the transformed plant cell or transformed plant tissue of (a); (c) growing the transgenic plant under suitable conditions to express the protein.

21. The method of claim 20, wherein the transgene encodes ethylene receptor etrl-1.

22. A method for producing a transgenic plant that produces longer-lasting flowers as compared to a wild type plant comprising: (a) introducing the transgene of claim 10 into a plant cell or plant tissue; (b) regenerating a transgenic plant from the transformed plant cell or transformed plant tissue of (a); and (c) selecting a transgenic plant that produces longer-lasting flowers as compared to a wild type plant.

23. A method for producing a transgenic plant that produces longer-lasting flowers as compared to a wild type plant comprising: (a) introducing the vector of claim 12 into a plant cell or plant tissue; and (b) regenerating a transgenic plant from the transformed plant cell or transformed plant tissue of (a); and (c) selecting a transgenic plant that produces longer-lasting flowers as compared to a wild type plant.

24. A transgenic plant produced by the method of claim 22 or 23.